Kane Biotech Announces Publication in Frontiers in Antibiotics Highlighting Advancements in Treating Antibiotic Tolerant Biofilms
MWN-AI** Summary
Kane Biotech Inc. (TSX-V:KNE) has made significant strides in the treatment of antibiotic-tolerant biofilms through its recently published research in Frontiers in Antibiotics. Co-authored by Kane's internal R&D leader, Dr. Jeyachchandran Visvalingam, and Dr. Sarvesh Logsetty from the University of Manitoba, the peer-reviewed article presents compelling evidence on the efficacy of revyve Antimicrobial Wound Gel against chronic wounds, which are often complicated by persistent biofilm infections.
The research highlights that revyve successfully targeted mature biofilms formed by Staphylococcus aureus and Pseudomonas aeruginosa, eliminating them even after significant antibiotic tolerance had developed. In both in vitro and ex vivo models, the gel was shown to drive bacterial populations down to undetectable levels within 24 to 72 hours after antibiotic pre-treatment, showcasing its potential as an essential tool in advanced wound care.
Kane Biotech's commitment to addressing the challenges of antibiotic resistance is underscored by the publication of this study, significantly contributing to the growing body of knowledge surrounding biofilm-targeted therapeutics. The publication serves not only as validation of their technology but also supports their ongoing commercialization efforts within the wound and burn care markets.
Dr. Robert Huizinga, Kane’s Interim CEO, expressed pride in having their research recognized in such a reputable journal, emphasizing the transparent review process that adds credibility to their findings. With revyve currently cleared by both the U.S. FDA and Health Canada, Kane Biotech is poised to transform the standard of care for chronic wounds, significantly improving patient outcomes through innovative antimicrobial solutions.
MWN-AI** Analysis
Kane Biotech Inc. (TSX-V: KNE) has recently made significant strides in the healthcare sector with the publication of findings in *Frontiers in Antibiotics* concerning its revyve Antimicrobial Wound Gel, which has shown promise in treating antibiotic-tolerant biofilms—a common hurdle in chronic wound management. This peer-reviewed study, a collaboration with researchers from the University of Manitoba, reinforces Kane's position as a leader in biofilm-targeted therapeutics.
For investors, the implications of this development are multifaceted. First, the efficacy of revyve against persistent and challenging bacterial infections, as demonstrated in rigorous testing, provides a potential competitive edge in a growing wound care market. Chronic wounds treated effectively not only improve patient outcomes but also reduce long-term healthcare costs, making revyve an attractive option for healthcare providers. As healthcare systems increasingly seek solutions to antibiotic resistance, Kane’s innovative approaches could capture a substantial market share.
Financially, this positive research can be viewed as a catalyst for shareholder value, potentially increasing demand for Kane's shares. The FDA and Health Canada clearances add regulatory credibility, further signaling to investors that Kanes' products are viable and trustworthy. However, caution is warranted; Kane faces the operational risks typical of biotech companies, including dependence on financing and market acceptance.
In summary, Kane Biotech presents an interesting opportunity for investors, especially given its recent advancements and the increasing demand for effective chronic wound care solutions. While maintaining a watchful eye on market fluctuations and operational challenges, positioning in Kane now could yield long-term benefits, particularly as it leads in addressing critical issues surrounding antibiotic resistance in the medical community.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from Kane Biotech and the University of Manitoba, detailing important scientific advancements in the fight against antibiotic-tolerant biofilms.
Key messages of the article as it relates to Kane’s revyve wound gel include:
- revyve Antimicrobial Wound Gel demonstrated strong activity against antibiotic-tolerant biofilms, a major barrier in the treatment of chronic wounds.
- In both in vitro and ex vivo models, revyve eliminated mature Staphylococcus aureus and Pseudomonas aeruginosa biofilms, even after they had developed high levels of antibiotic tolerance.
- Following antibiotic pre-treatment, which generated highly antibiotic-tolerant cells, revyve achieved large log-scale reductions in surviving populations, often driving bacterial counts below detectable limits within 24–72 hours.
- In summary, these results show that revyve effectively inactivates stubborn biofilms, supporting its potential as a valuable advanced-wound-care tool for improving healing outcomes in chronic, biofilm-laden wounds.
US FDA 510(k) cleared and Health Canada approved revyve Antimicrobial Wound Gel
The forthcoming publication, titled “Efficacy of a Novel Thermo-Reversible Wound Gel Against Antibiotic Tolerant Biofilm,” underscores Kane’s growing leadership in biofilm-targeted therapeutics and adds to the expanding body of evidence supporting innovative approaches to wound and burn management. First-authored by Dr. Jeyachchandran Visvalingam, Internal R&D Leader, and including contributions from Dr. Sarvesh Logsetty, renowned burn and trauma surgeon at the Max Rady College of Medicine, University of Manitoba, the study contributes meaningful insights into how thermo-reversible antibiofilm and antimicrobial technologies can address one of the most persistent challenges in modern wound care.
Frontiers in Antibiotics is a peer-reviewed, open-access journal that focuses on antibiotic development, resistance, and clinical applications.
The article can be viewed here.
“Having our research published in Frontiers in Antibiotics as an open-access article is an important milestone for Kane Biotech as we continue to commercialize revyve across wound and burn care markets,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “This peer-reviewed journal is recognized for its rigorous scientific standards and transparent review process. This publication reinforces the strength of our technology and supports our mission to bring advanced, biofilm-targeted solutions to patients.”
About Kane Biotech Inc. (TSX-V:KNE)
Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve Antimicrobial Wound Gel, revyve Antimicrobial Wound Gel Spray and revyve Antimicrobial Skin and Wound Cleanser are all U.S. FDA 510(k) cleared. revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray are also Health Canada approved. To learn more, visit revyvegel.com or revyvegel.ca.
Join Kane’s Distribution List & Social Media:
To stay informed on the latest developments, sign up for the Company’s email distribution list here.
Follow Kane
Website: kanebiotech.com
LinkedIn: https://www.linkedin.com/company/kanebiotech/
Presentation: Disrupting Biofilms to Save Limbs and Transform Wound Care
For more information:
| Dr. Robert Huizinga | Ray Dupuis |
| Interim CEO | Chief Financial Officer |
| Kane Biotech Inc. | Kane Biotech Inc. |
| rhuizinga@kanebiotech.com | rdupuis@kanebiotech.com |
| (780) 970-1100 | (204) 298-2200 |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0daf5c85-6ffb-4e70-8df7-301990f50291
FAQ**
How does Kane Biotech Inc. (KNE) plan to leverage the recent publication in Frontiers in Antibiotics to enhance market acceptance for its revyve products among healthcare professionals?
What specific strategies will Kane Biotech Inc. (KNBIF) implement to address the financial risks associated with its early-stage development and reliance on equity financing?
In what ways does Kane Biotech Inc. (KNE) intend to protect its intellectual property related to the innovative technologies behind revyve and market them effectively?
How does Kane Biotech Inc. (KNBIF) measure the long-term impact of its biofilm-targeted solutions on chronic wound care outcomes, and what clinical data supports this?
**MWN-AI FAQ is based on asking OpenAI questions about Kane Biotech Inc. (OTC: KNBIF).
NASDAQ: KNBIF
KNBIF Trading
13.9% G/L:
$0.0254 Last:
4,870 Volume:
$0.0254 Open:
